Skip to content
Review Open access

Multi-tissue miRNA networks in preterm birth: from molecular mechanisms to precision medicine

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 155 references
Medicine

TL;DR

The multi-tissue miRNA framework proposed in this review integrates miRNA biomarkers for early risk stratification with targeted therapeutic interventions, providing a new theoretical foundation for research directions in personalized risk assessment and targeted intervention strategies for PTB.

Abstract

Preterm birth (PTB) remains the leading cause of neonatal mortality and long-term complications worldwide, yet its molecular pathogenesis—particularly the coordinated regulation across different gestational tissues—is poorly understood. MicroRNAs (miRNAs) are key regulators of gene expression and exhibit tissue-specific patterns in pregnancy-related tissues, including the cervix, placenta, and amniotic membrane. This narrative review provides a comprehensive and integrative overview from a perspective of putative cross-tissue miRNA crosstalk. We summarize the differential miRNA expression profiles across gestational tissues and their associations with PTB, the tissue-specific mechanisms by which miRNAs regulate inflammatory responses, extracellular matrix remodeling, apoptosis, and barrier disruption, as well as the synergistic effects of multi-tissue-derived miRNAs and their potential as predictive biomarkers. We also evaluate the current status of miRNA-based therapeutic strategies. Our overview reveals that miRNA mimics (e.g., miR-21-5p, miR-199a-3p) and antagonists hold preclinical therapeutic potential in modulating inflammatory cascades and preserving cervical barrier function. However, clinical translation faces three major bottlenecks: the lack of pregnancy-specific delivery systems, safety concerns arising from the multi-target nature of miRNAs, and the challenge of targeting multi-tissue synergistic pathological changes with single-agent interventions. Emerging strategies—including exosome-based delivery, ligand-modified nanocarriers, and combination therapies—are currently being explored. The multi-tissue miRNA framework proposed in this review integrates miRNA biomarkers for early risk stratification with targeted therapeutic interventions, providing a new theoretical foundation for research directions in personalized risk assessment and targeted intervention strategies for PTB.

Read PDF

Similar papers

Open access Aug 2026

Placental microRNA signatures of spontaneous preterm birth

Potential biological mechanisms by which placental microRNA dysfunction might contribute to spontaneous preterm birth are highlighted and putative sPTB biomarkers that may be detectable in maternal circulation are highlighted.

Mariana Parenti, Elizabeth M. Kennedy, Evan J. Firsick et al. · 0 citations
Review Open access Sep 2026

miRNAs in Health and Disease

microRNAs (miRNAs) are small, non-coding RNA molecules (~19–24 nucleotides) that post-transcriptionally regulate gene expression by inducing mRNA degradation or translational repression. Since the discovery of lin-4 in 1993, a milestone honored with the 2024 Nobel Prize, miRNAs have been estimated to regulate over 60%...

T. Kaymaz · 0 citations
Review Open access Sep 2026

MicroRNAs in immune-related diseases: mechanism, functions and therapeutic perspectives

The biogenesis and biological functions of miRNAs are discussed and their regulatory roles in the pathogenesis of rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, multiple sclerosis, psoriasis, systemic lupus erythematosus, and atopic dermatitis are examined.

T. Tunç, Serap Yaman Ozer, Sema Mısır · 0 citations
Review Open access Sep 2026

Beyond the ceiling: A critical analysis of microRNA research in cutaneous T-cell lymphoma and a roadmap forward.

MicroRNAs (miRNAs) have been studied in cutaneous T-cell lymphoma (CTCL) for more than 15 years, revealing oncogenic and tumor-suppressive networks, the JAK/STAT-miRNA signaling circuit, diagnostic classifiers, and therapeutic miRNA targeting (Cobomarsen, targeting miRNA-155). Yet, no miRNA diagnostic has reached clini...

Maria Gluud, C. K. Vadivel, M. R. J. Namini et al. · 0 citations
2026

Integration of Omics Data to Identify Cancer-Related MicroRNA.

This chapter includes step-by-step protocols, example R code, and recommendations for integrating additional data layers such as copy number variation and DNA methylation, with the goal of improving the robustness and interpretability of miRNA-based analyses in cancer.

L. Cascione · 0 citations
Review Aug 2026

MicroRNAs and Their Crosstalk with Oncogenic Pathways in Gastric Cancer.

Current mechanistic insights into miRNA- mediated regulation of the aforementioned signaling highways are synthesized, context-dependent controversies arising from tumor heterogeneity and microbial influence are highlighted, and rational combinatorial strategies that may accelerate the development of next-generation, h...

Liu-Shan Wei, Jia Yu, Yan Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.